Pfizer, accelerating its research pace, hopes to launch 3 new drugs next year
Article Abstract:
Pfizer Inc. unveiled some of its plans to investors recently, plans to step up product launches from one per year to three. Drugs planned for 1999 launch include one for migraine treatment, one for treating atrial fibrillation and one it has partnered with Monsanto to develop, Celebrex for arthritis pain relief. The company estimates these products could ultimately mean $1 billion in sales. Other plans include expanding the use of Viagra to women.
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Merck drug said to help bone-building
Article Abstract:
Merck & Co.'s Fosamax osteoporosis drug enhances the effects of bone-building in hormone-replacement therapy in older women who have the disease. This is according to a new study conducted by Merck. The study is intended to respond to the concerns that physicians have about combining Fosamax with hormone-replacement therapy. This therapy can help women battle the osteoporosis disease.
Comment:
Fosamax osteoporosis drug enhances effects of bone-building in hormone-replacement therapy in older women who have disease
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Lion's desert prowl. New hopes for old dreams in the Pilbara
- Abstracts: Netscape jolts Web by allying with Excite Inc. Infoseek, Disney unit to launch new Internet site
- Abstracts: Some conceptual and research barriers to the utilization of knowledge. Knowledge research issues
- Abstracts: Pain under attack: Explosion in biotechnology drugs focuses on arthritis. Weight-loss drug shows some success in humans
- Abstracts: After years of being off track, VH1 hits its groove. NBC moves to sell goods to its viewers. Head of CBS quits in move seen as early; chief operating officer ascends to the top job